OncoMatch/Clinical Trials/NCT06596915
Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors
Is NCT06596915 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BA1302 for non-small cell lung cancer.
Treatment: BA1302 — This is a first-in-human (FIH), multicenter, open-label Phase I study to evaluate the safety, tolerability, PK profile, immunogenicity, and preliminary efficacy of BA1302 in patients with advanced solid malignancies. The study includes a dose-escalation phase (Part A) and a dose-expansion phase (Part B).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Pancreatic Cancer
Breast Carcinoma
Melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard therapy
Patients who have progressed on or after standard therapy, or are intolerant of standard therapy, or have no appropriate standard therapy available.
Cannot have received: chemotherapy
Exception: within 28 days prior to the first dose
Received any chemotherapy...within 28 days prior to the first dose.
Cannot have received: radiotherapy
Exception: within 28 days prior to the first dose
Received any...radiotherapy...within 28 days prior to the first dose.
Cannot have received: targeted therapy
Exception: within 28 days prior to the first dose
Received any...targeted therapy...within 28 days prior to the first dose.
Cannot have received: cell therapy
Exception: within 28 days prior to the first dose
Received any...cell therapy...within 28 days prior to the first dose.
Cannot have received: immunotherapy
Exception: within 28 days prior to the first dose
Received any...immunotherapy...within 28 days prior to the first dose.
Cannot have received: antibody-drug conjugate
Exception: within 28 days prior to the first dose
Received any...ADC medication...within 28 days prior to the first dose.
Cannot have received: other anti-cancer treatment
Exception: within 28 days prior to the first dose
Received any...other anti-cancer treatment within 28 days prior to the first dose.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify